EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

Xiuning Le, Christina Baik, Jessica Bauman, Jill Gilbert, Marcia S Brose, Juneko E Grilley-Olson, Tejas Patil, Ray McDermott, Luis E Raez, Jennifer M Johnson, Lin Shen, Makoto Tahara iD und 6 weitere

The Oncologist · 03.06.2024 · 29 (6) · e779-e788

DOI: 10.1093/oncolo/oyac080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.05.2022. Verfasst von Xiuning Le und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Bayer Healthcare and Loxo Oncology, Inc, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer. We report the efficacy and safety of larotrectinib in patients with TRK fusion-positive salivary gland cancers. Patients and Methods Patients with TRK fusion-positive salivary gland cancer treated with larotrectinib were identified from two clinical trials (NCT02122913 and NCT02576431). Patients received larotrectinib 100 mg twice daily (BID) except for one patient who received 150 mg BID in the phase I trial. The primary endpoint was objective response rate (ORR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1.

Results

At the data cut-off (July 20, 2020), 24 patients with TRK fusion-positive salivary gland cancer had been treated. The most common histologies were secretory carcinoma (54%), adenocarcinoma (25%), and mucoepidermoid carcinoma (13%). All 24 patients had an ETV6-NTRK3 gene fusion. The ORR was 92% (95% confidence interval, 73-99). Best overall response was complete response in three (13%) patients, partial response in 19 (79%), and progressive disease in two (8%). The rate of progression-free survival at 24 months was 78% (median follow-up 30.9 months). Most treatment-related adverse events (AEs) were grade 1-2, and no patients discontinued treatment due to AEs.

Conclusion

Larotrectinib demonstrated robust and durable efficacy in patients with TRK fusion-positive salivary gland tumors of various histologies, and a favorable safety profile. These findings support NTRK gene fusion testing in patients with advanced salivary gland cancers. ClinicalTrials.gov numbers NCT02122913 and NCT02576431.

Schlagwörter

Stichwörter der Autor:innen

NTRKTRKgene fusionlarotrectinibsalivary gland tumors

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Vanderbilt University, Nashville, TN, USA.
  • Sidney Kimmel Cancer Center of Jefferson University Health, Philadelphia, PA, USA.
  • University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.

ORCID-Profile: Makoto Tahara, Alexander Drilon

Förderung

  • NCI NIH HHS
  • Bayer Healthcare and Loxo Oncology, Inc
  • Eli Lilly and Company
  • NIH
  • NCI
  • Cancer Center Support

Zitieren

APA

Le, X., Baik, C., Bauman, J., Gilbert, J., Brose, M. S., Grilley-Olson, J. E., Patil, T., McDermott, R., Raez, L. E., Johnson, J. M., Shen, L., Tahara, M., Ho, A. L., Norenberg, R., Dima, L., Brega, N., Drilon, A., & Hong, D. S. (2024). Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. The Oncologist, 29(6), e779-e788. https://doi.org/10.1093/oncolo/oyac080

Vancouver

Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, et al. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. The Oncologist. 2024;29(6):e779-e788. doi:10.1093/oncolo/oyac080

BibTeX
@article{Le2024,
  author = {Le, Xiuning and Baik, Christina and Bauman, Jessica and Gilbert, Jill and Brose, Marcia S and Grilley-Olson, Juneko E and Patil, Tejas and McDermott, Ray and Raez, Luis E and Johnson, Jennifer M and Shen, Lin and Tahara, Makoto and Ho, Alan L and Norenberg, Ricarda and Dima, Laura and Brega, Nicoletta and Drilon, Alexander and Hong, David S},
  title = {Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {6},
  pages = {e779--e788},
  doi = {10.1093/oncolo/oyac080}
}
Kostenlos starten →